Evidence map›Paper›PMID 29174717›Full record

ArticleJournal of immunological methods2018

Comparison of CyTOF assays across sites: Results of a six-center pilot study.

Michael D Leipold, Gerlinde Obermoser, Craig Fenwick, Katja Kleinstuber, Narges Rashidi, John P McNevin, Allison N Nau, Lisa E Wagar, Virginie Rozot, Mark M Davis and 6 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunological methods, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Ocrelizumab Impairs the Phenotype and Function of Memory CD8Neurology(R) neuroimmunology & neuroinflammation · 2023
    Article
  10. Article
  11. CyTOFFrontiers in immunology · 2022
    Review
  12. Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  13. Review
  14. Making the most of high-dimensional cytometry data.Immunology and cell biology · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Michael D LeipoldHuman Immune Monitoring Center, Stanford University, Stanford, CA, USA. Electronic address: mleipold@stanford.edu.
Gerlinde ObermoserHuman Immune Monitoring Center, Stanford University, Stanford, CA, USA.
Craig FenwickCentre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Katja KleinstuberRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Narges RashidiRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
John P McNevinFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Allison N NauInstitute for Transplantation and Immunity, Stanford University, Stanford, CA, USA.
Lisa E WagarInstitute for Transplantation and Immunity, Stanford University, Stanford, CA, USA.
Virginie RozotSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Mark M DavisInstitute for Transplantation and Immunity, Stanford University, Stanford, CA, USA.
Stephen DeRosaFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Giuseppe PantaleoCentre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Bruce D WalkerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Lars R OlsenDTU Bioinformatics, Technical University of Denmark, Copenhagen, Denmark.
Holden T MaeckerHuman Immune Monitoring Center, Stanford University, Stanford, CA, USA.
Stanford University · USRagon Institute of MGH, MIT and Harvard · USFred Hutch Cancer Center · USUniversity Hospital of Lausanne · CHUniversity of Cape Town · ZATechnical University of Denmark · DK

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
NIAID NIH HHS U19 AI057229NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

For more than five years, high-dimensional mass cytometry has been employed to study immunology. However, these studies have typically been performed in one laboratory on one or few instruments. We present the results of a six-center study using healthy control human peripheral blood mononuclear cells (PBMCs) and commercially available reagents to test the intra-site and inter-site variation of mass cytometers and operators. We used prestained controls generated by the primary center as a reference to compare against samples stained at each individual center. Data were analyzed at the primary center, including investigating the effects of two normalization methods. All six sites performed similarly, with CVs for both Frequency of Parent and median signal intensity (MSI) values<30%. Increased background was seen when using the premixed antibody cocktail aliquots at each site, suggesting that cocktails are best made fresh. Both normalization methods tested performed adequately for normalizing MSI values between centers. Clustering algorithms revealed slight differences between the prestained and the sites-stained samples, due mostly to the increased background of a few antibodies. Therefore, we believe that multicenter mass cytometry assays are feasible.

Indexed as

AntibodiesFlow CytometryHealthy VolunteersHumansImmunophenotypingLeukocytes, MononuclearMass SpectrometryPilot ProjectsReference StandardsAntibodiesClusteringCyTOFMass cytometryMulticenterNormalizationStandardization

Identifiers

PMID29174717
PMCPMC5805584
OpenAlexW2768196935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.